- Why Research
- Our Impact
- Get Involved
- About BCRF
- Contact Us
- Cancer Divides. We Unite.
You are here
Antonio C. Wolff, MD
Professor of Oncology
Member, Breast Cancer Program
Sidney Kimmel Comprehensive Cancer Center
Johns Hopkins University
on behalf of the Translational Breast Cancer Research Consortium
Seeking to accelerate new treatments to benefit patients through focused clinical trials.
The Translational Breast Cancer Research Consortium (TBCRC) is actively accruing patients to 10 clinical trials in all breast cancer types with 7 more trials under development.
Results from these trials provide valuable insight that will guide personalized treatment for various subtypes of breast cancer.
Dr. Wolff serves as the Executive Officer of the Translational Breast Cancer Research Consortium (TBCRC), a clinical research consortium, initiated in 2005 with support from BCRF.
The TBCRC unites the efforts of many leading breast cancer programs from top academic medical centers throughout the United States to pursue clinical trials that integrate clinical and laboratory studies in an effort to accelerate progress in breast cancer clinical research.
Since its inception, 47 TBCRC clinical trials involving over 4300 patients have been approved. Results from the first 20 completed TBCRC trials have been presented at national meetings. The clinical results, as well as some correlative work, from 17 TBCRC trials have been published in peer-reviewed journals.
TBCRC trials continue to provide insight into the development of more effective and individualized treatments for various subtypes of breast cancer. Funding from BCRF remains critical to bring together scientific resources and researchers to develop new strategies to reduce the burden of breast cancer.
The TBCRC network is engaged in other BCRF- supported initiatives including the International Male Breast Cancer Project (lead investigators, Fatima Cardoso and Sharon Giordano) and the Evelyn H. Lauder Founder's Fund, a multi-year project focused on dissecting the molecular underpinning of breast cancer metastasis.
Antonio Wolff is a Professor of Oncology at the Johns Hopkins University School of Medicine, a member of the Breast and Ovarian Cancer Program at the Johns Hopkins Kimmel Comprehensive Cancer Center, and a breast cancer medical oncologist with expertise in clinical trials, biomarkers development and implementation, survivorship, and clinical practice guidelines. Dr .Wolff received his medical degree from the Universidade Federal do Rio de Janeiro, completed a residency at Mount Sinai (NY) and fellowship at Johns Hopkins. His expertise is in collaborative research in breast cancer clinical trials, the integration of research findings into clinical practice, biomarker development and implementation, and in quality initiatives. Dr. Wolff was a member of the Breast Cancer Guidelines Committee of the National Comprehensive Cancer Network between 2000 and 2014. He sat on the Clinical Practice Guidelines Committee of the American Society of Clinical Oncology from 2002 to 2008 (Chair, 2006-2007), and was a member of the first ASCO Quality Care Committee. Dr. Wolff is also interested in survivorship, needs assessments, and educational needs of breast cancer patients. At Johns Hopkins, he co-chairs the Cancer Outcomes & Health Services Research Interest Group. He chaired the Cancer Center Clinical Research Scientific Review Committee and was a member of the School of Medicine CME Advisory Board. Since 2006, he has been Executive Officer of the Translational Breast Cancer Research Consortium (www.tbcrc.org), a clinical research consortium that involves all breast cancer SPOREs and major academic breast cancer programs. Dr. Wolff has received research funding from the National Cancer Institute, Avon Foundation, Breast Cancer Research Foundation, and Susan G. Komen Breast Cancer Foundation. In January 2014 he became Co-Chair of the Breast Cancer Committee of ECOG-ACRIN. He is Associate Editor of the Journal of Clinical Oncology